OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN DWIGHT | — |
| AMELIA SUERMANN | — |
Health Issues HCR
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, and BIOSECURE Act, and the Ensuring Pathways to Innovate Cures (EPIC) Act, HR 7174.
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN DWIGHT | — |
| AMELIA SUERMANN New | — |
Budget/Appropriations BUD
Provisions related to the Continuing Appropriations and Other Matters Act, 2025 (HR 9494)
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN DWIGHT | — |
| AMELIA SUERMANN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.